Method for synthesizing alogliptin intermediate

A technology for intermediates and compounds, applied in the field of intermediates for the production of dipeptidyl peptidase inhibitor alogliptin, can solve problems such as troublesome handling

CN105085475AActive Publication Date: 2015-11-25SHANGHAI SYNCORES TECH INC
4 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2015-11-25

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention provides a method for synthesizing an intermediate V. The method comprises: (a) allowing a compound I and a compound II to react while being heated in a solvent under an alkaline condition to obtain an intermediate III; and (b) the intermediate III reacting with a compound IV in the solvent under the alkaline condition to obtain the intermediate V. The intermediate V can be used to synthesize alogliptin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The present invention relates to a process for the synthesis of intermediates suitable for the production of the dipeptidyl peptidase inhibitor alogliptin. Background technique:

[0002] Diabetes mellitus is a series of clinical syndromes caused by absolute or relative insufficiency of insulin in the body. At present, the treatment of diabetes is mainly a combination of diet control combined with hypoglycemic drugs or insulin supplementation. People with type 2 diabetes cannot normally secrete or respond to insulin, which regulates blood sugar. Prolonged high blood sugar increases the risk of serious syndromes, including heart disease, nerve and kidney damage. At present, oral hypoglycemic drugs commonly used in clinical practice mainly include biguanides, sulfonylureas, thiazolidinediones, meglitinides, and α-glucosidase inhibitors. Dipeptidyl peptidase IV (DPP-IV) is one of the key enzymes that mainly promote the degradation and inactivation of gl...

Examples

Embodiment 1

[0040]

Embodiment 1-1

[0042] Add 6-chloro-3-methyluracil (30.2g, 0.19mol) and (R)-3-tert-butoxycarbonylaminopiperidine (37.4g, 0.19mol) into a 500ml reaction flask, add 180ml of acetonitrile, 36.0 g (0.28 mol) of N,N-diisopropylethylamine was stirred and heated to 78-82°C, and reacted for 10 hours. Stop heating, cool to 15-25°C, filter under reduced pressure, rinse the filter cake with 100ml of acetonitrile and drain to obtain 55.1g of off-white solid, yield: 90.8%. 1 HNMR(DMSO)δ: 10.57(br,1H), 6.87(d,1H), 4.79(s,1H), 3.59(dd,1H), 3.02(s,3H), 2.84~2.69(br,2H), 1.76~1.63(br,2H), 1.57~1.41(br,2H), 1.36(s,9H); 1.22~1.25(br,2H); MS + = 325.2.

Embodiment 1-2~1-12

[0044] Referring to Example 1-1, change the substituent R 2 , alkali, solvent and alkali and the mol ratio of I, yield result is as shown in table 1:

[0045] Table 1

[0046]

[0047]